Literature DB >> 23872417

Modulation of NMDA receptor at the synapse: promising therapeutic interventions in disorders of the nervous system.

Manuela Mellone1, Fabrizio Gardoni2.   

Abstract

There is general agreement that excessive activation of N-methyl-D-aspartate (NMDA) receptors plays a key role in mediating at least some aspects of synaptic dysfunction in several central nervous system disorders. On this view, in the last decades, research focused on the discovery of different compounds able to reduce NMDA receptor activity, such as classical and/or subunit-specific antagonists. However, the increasing body of knowledge on specific signaling pathways downstream NMDA receptors led to the identification of new pharmacological targets for NMDA receptor-related pathological conditions. Moreover, besides over-activation, several studies indicated that also abnormal NMDA receptor trafficking, resulting in the modification of the receptor subunit composition at the synapse, has a major role in the pathogenesis of several brain disorders. For this reason, the discovery of the molecular mechanisms regulating the abundance of synaptic versus extra-synaptic NMDA receptors as well as the activation of the specific signaling pathways downstream the different NMDA receptor subtypes is needed for the development of novel therapeutic approaches for NMDA receptor-dependent synaptic dysfunction.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cell-permeable peptides; Central nervous system disorders; N-methyl-D-aspartate receptor; Post-synaptic density; Preclinical studies; Trafficking

Mesh:

Substances:

Year:  2013        PMID: 23872417     DOI: 10.1016/j.ejphar.2013.04.054

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  12 in total

1.  NMDA Receptor Plasticity in the Hypothalamic Paraventricular Nucleus Contributes to the Elevated Blood Pressure Produced by Angiotensin II.

Authors:  Michael J Glass; Gang Wang; Christal G Coleman; June Chan; Evgeny Ogorodnik; Tracey A Van Kempen; Teresa A Milner; Scott D Butler; Colin N Young; Robin L Davisson; Costantino Iadecola; Virginia M Pickel
Journal:  J Neurosci       Date:  2015-07-01       Impact factor: 6.167

2.  A Novel Negative Allosteric Modulator Selective for GluN2C/2D-Containing NMDA Receptors Inhibits Synaptic Transmission in Hippocampal Interneurons.

Authors:  Sharon A Swanger; Katie M Vance; Timothy M Acker; Sommer S Zimmerman; John O DiRaddo; Scott J Myers; Christoffer Bundgaard; Cara A Mosley; Samantha L Summer; David S Menaldino; Henrik S Jensen; Dennis C Liotta; Stephen F Traynelis
Journal:  ACS Chem Neurosci       Date:  2017-11-02       Impact factor: 4.418

3.  KIF17 Modulates Epileptic Seizures and Membrane Expression of the NMDA Receptor Subunit NR2B.

Authors:  Yan Liu; Xin Tian; Pingyang Ke; Juan Gu; Yuanlin Ma; Yi Guo; Xin Xu; Yuanyuan Chen; Min Yang; Xuefeng Wang; Fei Xiao
Journal:  Neurosci Bull       Date:  2022-06-09       Impact factor: 5.271

4.  Glutamatergic agents for OCD and related disorders.

Authors:  Christopher Pittenger
Journal:  Curr Treat Options Psychiatry       Date:  2015-09

5.  Glutamatergic mechanisms in L-DOPA-induced dyskinesia and therapeutic implications.

Authors:  Manuela Mellone; Fabrizio Gardoni
Journal:  J Neural Transm (Vienna)       Date:  2018-01-31       Impact factor: 3.575

Review 6.  Modulation of the glutamatergic transmission by Dopamine: a focus on Parkinson, Huntington and Addiction diseases.

Authors:  Fabrizio Gardoni; Camilla Bellone
Journal:  Front Cell Neurosci       Date:  2015-03-02       Impact factor: 5.505

Review 7.  Mechanisms of NOS1AP action on NMDA receptor-nNOS signaling.

Authors:  Michael J Courtney; Li-Li Li; Yvonne Y Lai
Journal:  Front Cell Neurosci       Date:  2014-08-27       Impact factor: 5.505

8.  NMDA receptor GluN2A/GluN2B subunit ratio as synaptic trait of levodopa-induced dyskinesias: from experimental models to patients.

Authors:  Manuela Mellone; Jennifer Stanic; Ledia F Hernandez; Elena Iglesias; Elisa Zianni; Annalisa Longhi; Annick Prigent; Barbara Picconi; Paolo Calabresi; Etienne C Hirsch; Jose A Obeso; Monica Di Luca; Fabrizio Gardoni
Journal:  Front Cell Neurosci       Date:  2015-07-06       Impact factor: 5.505

9.  Rabphilin 3A retains NMDA receptors at synaptic sites through interaction with GluN2A/PSD-95 complex.

Authors:  Jennifer Stanic; Mario Carta; Ivano Eberini; Silvia Pelucchi; Elena Marcello; Armando A Genazzani; Claudia Racca; Christophe Mulle; Monica Di Luca; Fabrizio Gardoni
Journal:  Nat Commun       Date:  2015-12-18       Impact factor: 14.919

10.  Amantadine and the Risk of Dyskinesia in Patients with Early Parkinson's Disease: An Open-Label, Pragmatic Trial.

Authors:  Aryun Kim; Young Eun Kim; Ji Young Yun; Han-Joon Kim; Hui-Jun Yang; Woong-Woo Lee; Chae Won Shin; Hyeyoung Park; Yu Jin Jung; Ahro Kim; Yoon Kim; Mihee Jang; Beomseok Jeon
Journal:  J Mov Disord       Date:  2018-05-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.